Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis

Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis

Background: The hypomethylating agents (HMAs) azacitidine (AZA) and decitabine (DAC) have been widely used in patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS). However, few direct clinical trials have been carried out to compare the efficacy and adverse ev...

Full description

Bibliographic Details
Main Authors:	Jiale Ma, Zheng Ge
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Pharmacology
Subjects:	decitabine azacitidine acute myeloid leukemia higher-risk myelodysplastic syndrome network meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.701690/full

Similar Items

Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis
by: Frontiers Production Office
Published: (2023-05-01)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
by: Jehad Almasri, et al.
Published: (2018-09-01)

Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis
by: Bingbing Wen, et al.
Published: (2020-03-01)

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
by: Jorge Labrador, et al.
Published: (2022-05-01)

Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis
by: Miriam Saiz-Rodríguez, et al.
Published: (2021-11-01)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
by: Guangjie Zhao, et al.
Published: (2021-09-01)

Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience
by: İbrahim Ethem Pınar, et al.
Published: (2021-03-01)

The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis
by: Yufeng Du, et al.
Published: (2023-12-01)

Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
by: Smith Kungwankiattichai, et al.
Published: (2022-02-01)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
by: Mariarita Sciumè, et al.
Published: (2023-03-01)

Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis
by: Xuefeng Li, et al.
Published: (2022-08-01)

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
by: Fernando Vieira Pericole, et al.
Published: (2019-01-01)

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
by: Nicholas J. Short, et al.
Published: (2022-01-01)

A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy
by: Asude Kara, et al.
Published: (2017-05-01)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
by: Vincent G. Sorrentino, et al.
Published: (2021-07-01)

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience
by: Francesco Angotzi, et al.
Published: (2024-04-01)

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
by: Briot T, et al.
Published: (2017-11-01)

Relationship between Altered miRNA Expression and DNA Methylation of the DLK1-DIO3 Region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes
by: Michaela Dostalova Merkerova, et al.
Published: (2018-09-01)

Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report
by: Yuina Akagi, et al.
Published: (2023-08-01)

High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia
by: Sing-Ting Wang, et al.
Published: (2022-11-01)

Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis
by: Xinhui Zheng, et al.
Published: (2022-06-01)

Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine
by: Lu Liu, et al.
Published: (2024-02-01)

Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine
by: Mihee Kim, et al.
Published: (2024-12-01)

Long-Lasting Remission in De Novo Breast Myeloid Sarcoma Treated with Decitabine and Radiotherapy
by: Carla Minoia, et al.
Published: (2019-07-01)

Decitabine combined with arsenic trioxide inhibits proliferation and promotes apoptosis of acute myeloid leukemia cell lines
by: LIU Yue, CAO Yang, GU Weiying, SHANG Limei, LIU Yan
Published: (2023-04-01)

The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine
by: Alicja Pawlak, et al.
Published: (2022-03-01)

The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine
by: Yi Li, et al.
Published: (2024-01-01)

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes
by: Seungyoun Kim, et al.
Published: (2021-12-01)

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome
by: Jonathan Pan, et al.
Published: (2020-10-01)

Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia
by: Fang Zheng, et al.
Published: (2023-12-01)

A Case of Organizing Pneumonia Following Azacitidine Treatment for Myelodysplastic Syndrome
by: Kelly Ann Hutchinson, et al.
Published: (2023-05-01)

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
by: Shi M, et al.
Published: (2019-09-01)

Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells
by: Sonia Abou Najem, et al.
Published: (2019-11-01)

An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia
by: Anwarul Islam
Published: (2023-08-01)

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome
by: Francesco D’Alò, et al.
Published: (2021-04-01)

Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination
by: Daniela Taurino, et al.
Published: (2021-08-01)

Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report
by: Juliana Todaro, et al.

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
by: Mihee Kim, et al.
Published: (2023-07-01)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
by: Louise Laloi, et al.
Published: (2023-03-01)

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group
by: Michael Leisch, et al.
Published: (2022-05-01)